Activity of Galidesivir in a Hamster Model of SARS-CoV-2.

Journal Article (Journal Article)

Coronavirus disease 2019 (COVID-19) has claimed the lives of millions of people worldwide since it first emerged. The impact of the COVID-19 pandemic on public health and the global economy has highlighted the medical need for the development of broadly acting interventions against emerging viral threats. Galidesivir is a broad-spectrum antiviral compound with demonstrated in vitro and in vivo efficacy against several RNA viruses of public health concern, including those causing yellow fever, Ebola, Marburg, and Rift Valley fever. In vitro studies have shown that the antiviral activity of galidesivir also extends to coronaviruses. Herein, we describe the efficacy of galidesivir in the Syrian golden hamster model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Treatment with galidesivir reduced lung pathology in infected animals compared with untreated controls when treatment was initiated 24 h prior to infection. These results add to the evidence of the applicability of galidesivir as a potential medical intervention for a range of acute viral illnesses, including coronaviruses.

Full Text

Duke Authors

Cited Authors

  • Taylor, R; Bowen, R; Demarest, JF; DeSpirito, M; Hartwig, A; Bielefeldt-Ohmann, H; Walling, DM; Mathis, A; Babu, YS

Published Date

  • December 21, 2021

Published In

Volume / Issue

  • 14 / 1

PubMed ID

  • 35062212

Pubmed Central ID

  • PMC8780270

Electronic International Standard Serial Number (EISSN)

  • 1999-4915

Digital Object Identifier (DOI)

  • 10.3390/v14010008


  • eng

Conference Location

  • Switzerland